A composition and method for treating tumor cells are provided. The composition includes at least one ebastine derivative having a structure according to Formula I. The method include administering, to a patient in need thereof, an effective amount of the composition including at least one ebastine derivative having the structure according to Formula I.

In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

A method of attenuating opioid induced cardio and/or respiratory depression in a subject in need thereof includes administering to the subject an amount of a composition comprising a nitroxide compound effective to attenuate the opioid induced cardio and/or respiratory depression.

A method of attenuating opioid induced cardio and/or respiratory depression in a subject in need thereof includes administering to the subject an amount of a composition comprising a nitroxide compound effective to attenuate the opioid induced cardio and/or respiratory depression.

The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

A method of treatment is disclosed. The method comprises administering to a human subject having or at risk of developing a disease associated with decreased expression of one or more genes encoding cytochrome P450, an effective amount of a nitroxide antioxidant, wherein the nitroxide antioxidant increases an expression level of one or more genes encoding cytochrome p450 enzymes.

A method of treatment is disclosed. The method comprises administering to a human subject having or at risk of developing a disease associated with decreased expression of one or more genes encoding cytochrome P450, an effective amount of a nitroxide antioxidant, wherein the nitroxide antioxidant increases an expression level of one or more genes encoding cytochrome p450 enzymes.

Some embodiments disclosed herein include a method for increasing an expression level of a gene. The methods include administering an effective amount of a nitroxide antioxidant to a human subject having a decreased expression level of SIRT2, whereby expression level of the gene is increased.

Some embodiments disclosed herein include a method for increasing an expression level of a gene. The methods include administering an effective amount of a nitroxide antioxidant to a human subject having a decreased expression level of SIRT2, whereby expression level of the gene is increased.